D Rey

Summary

Country: France

Publications

  1. ncbi request reprint High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus
    D Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    J Med Virol 57:75-9. 1999
  2. doi request reprint High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients
    D Rey
    COREVIH, Hopitaux Universitaires, Strasbourg, France
    J Antimicrob Chemother 63:380-8. 2009
  3. ncbi request reprint Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients
    David Rey
    Centre d information et de soins de l immunodeficience humaine, Clinique Medicale A, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg, France
    J Acquir Immune Defic Syndr 43:530-4. 2006
  4. ncbi request reprint [Hepatitis A seroprevalence in HIV-infected patients]
    D Rey
    Centre d information et de soins de l immunodeficience humaine, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg Cedex, France
    Med Mal Infect 35:402-6. 2005
  5. ncbi request reprint Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV
    David Rey
    Hopitaux Universitaires Strasbourg, Strasbourg, France
    J Acquir Immune Defic Syndr 37:1454-6. 2004
  6. ncbi request reprint [Osteopathies that weaken HIV-infected patients]
    David Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg
    Presse Med 32:1857-63. 2003
  7. ncbi request reprint Prevalence and persistence of TT virus DNA in HIV1-infected individuals
    D Rey
    Center for Human Immunodeficiency Disease, Medical Clinic, University Hospital, Place de l Hôpital 1, F 67091 Strasbourg, France
    Infection 31:226-31. 2003
  8. ncbi request reprint [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results]
    D Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg, France
    Pathol Biol (Paris) 49:559-66. 2001
  9. ncbi request reprint Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy
    D Rey
    Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 18:137-41. 1999
  10. doi request reprint Post-exposure prophylaxis for HIV infection
    David Rey
    Le Trait d Union, Centre de Soins de l Infection par le VIH, NHC, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg, France
    Expert Rev Anti Infect Ther 9:431-42. 2011

Detail Information

Publications18

  1. ncbi request reprint High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus
    D Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    J Med Virol 57:75-9. 1999
    ....
  2. doi request reprint High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients
    D Rey
    COREVIH, Hopitaux Universitaires, Strasbourg, France
    J Antimicrob Chemother 63:380-8. 2009
    ..The once-daily combination of lamivudine, tenofovirDF and nevirapine has not been evaluated in a clinical trial...
  3. ncbi request reprint Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients
    David Rey
    Centre d information et de soins de l immunodeficience humaine, Clinique Medicale A, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg, France
    J Acquir Immune Defic Syndr 43:530-4. 2006
    ..A regimen of once-daily zidovudine (ZDV), 3TC, ABC, and TDF showed an acceptable virologic success rate, however...
  4. ncbi request reprint [Hepatitis A seroprevalence in HIV-infected patients]
    D Rey
    Centre d information et de soins de l immunodeficience humaine, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg Cedex, France
    Med Mal Infect 35:402-6. 2005
    ..The authors had for aim to prospectively study the hepatitis A seroprevalence of an HIV-infected population, followed-up in an outpatient clinic (CISIH Strasbourg)...
  5. ncbi request reprint Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV
    David Rey
    Hopitaux Universitaires Strasbourg, Strasbourg, France
    J Acquir Immune Defic Syndr 37:1454-6. 2004
    ..We believe that such a short course (4 days) of 200-mg NVP treatment once a day in combination with 2 nucleoside analogues for 1 month is clinically and biologically safe...
  6. ncbi request reprint [Osteopathies that weaken HIV-infected patients]
    David Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg
    Presse Med 32:1857-63. 2003
    ..However, it is probable that the classical risk factors for osteoporosis are often implied...
  7. ncbi request reprint Prevalence and persistence of TT virus DNA in HIV1-infected individuals
    D Rey
    Center for Human Immunodeficiency Disease, Medical Clinic, University Hospital, Place de l Hôpital 1, F 67091 Strasbourg, France
    Infection 31:226-31. 2003
    ..TT virus (TTV) is a recently discovered virus with a high DNA prevalence in different populations. Its role in pathogenesis is uncertain, particularly in immunocompromised patients...
  8. ncbi request reprint [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results]
    D Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg, France
    Pathol Biol (Paris) 49:559-66. 2001
    ..Treatment re-initiation induces a good response, but virologically transient in most cases. Patients with a shift to wild-type virus seem to have a better response...
  9. ncbi request reprint Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy
    D Rey
    Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 18:137-41. 1999
    ..In cases of Aspergillus renal abscess in HIV-infected patients, surgery is the treatment of choice, especially in the current era of highly active antiretroviral therapy...
  10. doi request reprint Post-exposure prophylaxis for HIV infection
    David Rey
    Le Trait d Union, Centre de Soins de l Infection par le VIH, NHC, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg, France
    Expert Rev Anti Infect Ther 9:431-42. 2011
    ..The initial evaluation of an exposed individual is presented, as well as the follow-up during and after treatment...
  11. ncbi request reprint Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load
    D Rey
    CISIH, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    Vaccine 18:1161-5. 2000
    ..The effects on HIV-1 viral load are limited...
  12. ncbi request reprint High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1
    D Rey
    CISIH, Clinique Médicale A Hôpitaux Universitaires, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 19:721-4. 2000
    ..GBV-C/HGV infection was frequent in this group of HIV-infected patients and was associated with older age, lower CD4 + cell counts, and the presence of hepatitis B surface antigen...
  13. ncbi request reprint Quantitation of hepatitis C virus RNA in saliva and serum of patients coinfected with HCV and human immunodeficiency virus
    D Rey
    Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    J Med Virol 63:117-9. 2001
    ..003), but not between quantifications (P = 0.57). This first study reporting significant amounts of HCV RNA in saliva could have important implications for HCV epidemiology...
  14. ncbi request reprint Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks
    D Rey
    Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg Cedex, France
    J Acquir Immune Defic Syndr 27:459-62. 2001
    ..One AIDS patient experienced a single cutaneous recurrence of Kaposi's sarcoma after 40 weeks on EFV. Replacing PI with EFV in patients with optimal pVL suppression appears to be safe both virologically and immunologically...
  15. doi request reprint Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study
    Lionel Piroth
    Infectious Diseases Department, University Hospital, and University of Burgungy, Dijon, France
    Hepatology 52:1915-21. 2010
    ..The duration of treatment should be modulated according to RVR, with a 24-week course for patients presenting RVR and a 48-week course for those who do not, irrespectively of HCV genotype...
  16. ncbi request reprint Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study
    Jean Jacques Parienti
    Epidemiologie, Systemes d Informations, Modelisation, Institut National de la Sante et de la Recherche Medicale U707, Paris, France
    Clin Infect Dis 45:263-6. 2007
    ..04). A switch to nevirapine was associated with no severe adverse events...
  17. ncbi request reprint First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes
    Valerie Potard
    INSERM, UMR S 720, Paris, France
    Antivir Ther 12:317-24. 2007
    ....
  18. ncbi request reprint Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    AIDS 21:1323-31. 2007
    ..To describe the characteristics of hepatitis B (HBV) infection in HIV-infected patients and the impact of anti-HBV treatments...